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Abstract 
Background: Currently, graphene oxide has attracted growing attention as a drug delivery system due to its unique 
characteristics. Furthermore, utilization of microRNAs as biomarkers and therapeutic strategies would be particularly 
attractive because of their biological mechanisms and relatively low toxicity. Therefore, we have developed func-
tionalized nanocompounds consisted of graphene oxide, quantum dots and microRNA, which induced cancer cells 
apoptosis along with targeted imaging.
Results: In the present study, we synthesized a kind of graphene-P-gp loaded with miR-122-InP@ZnS quantum 
dots nanocomposites (GPMQNs) that, in the presence of glutathione, provides controlled release of miR-122. The 
miR-122 actively targeted liver tumor cells and induced their apoptosis, including drug-resistant liver tumor cells. 
We also explored the near-infrared fluorescence and potential utility for targeting imaging of InP@ZnS quantum 
dots. To further understand the molecular mechanism of GPMQNs-induced apoptosis of drug-resistant HepG2/ADM 
hepatoma cells, the relevant apoptosis proteins and signal pathways were explored in vitro and in vivo. Furthermore, 
near-infrared GPMQNs, which exhibited reduced photon scattering and auto-fluorescence, were applied for tumor 
imaging in vivo to allow for deep tissue penetration and three-dimensional imaging.
Conclusion: In conclusion, techniques using GPMQNs could provide a novel targeted treatment for liver cancer, 
which possessed properties of targeted imaging, low toxicity, and controlled release.
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Background
Liver cancer is the third-leading cause of cancer-related 
death in the world. The high-incidence regions include 
sub-Saharan Africa, the People’s Republic of China, Hong 
Kong, and Taiwan [1]. Chemotherapy is an important 
treatment for liver cancer, but cancer cells can acquire 
resistance to a wide variety of unrelated drugs when they 
are exposed to a chemotherapeutic agent. This phenom-
enon is termed multi-drug resistance (MDR). The molec-
ular basis of a major form of MDR is the overexpression 
of P-glycoprotein (P-gp) and the increased activity of 
glutathione transferase (GST) [2–4]. Overcoming drug 
resistance to chemotherapy has become one of the pri-
mary goals of modern approaches to cancer therapy.
The application of nanotechnology in cancer treatment 
offers some exciting possibilities, including the possibil-
ity of destroying cancer tumors with minimal damage 
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to healthy tissues and organs, as well as the detection 
and elimination of developing tumors [5, 6]. Recently, 
liposomes, metal nanocarriers and polymers have been 
investigated for their potential multifunctional uses as 
therapeutic agents, delivery vehicles and imaging agents 
capable of being visualized by magnetic resonance imag-
ing (MRI) or optical imaging techniques [7, 8]. The sur-
faces of these nanocarriers are typically conjugated with 
a targeting molecule such as a specific antibody (e.g., an 
antibody against P-gp on the surface of drug resistant 
tumor cells) [9]. The key issues in this process include the 
design and synthesis of nanocarriers, the choice of tar-
geting molecules, the assembly of drug nanocarriers and 
targeting molecules for the integration of diagnosis and 
treatment [10].
As an important biomarker and imaging nano-optical 
probe, quantum dots (QDs) play an important role in cell 
labeling and in vivo imaging [11, 12]. However, because 
traditional QDs contain lead, cadmium, mercury or 
other high toxic heavy metals, the use of fluorescent QDs 
in vitro and in vivo has been restricted. Near-infrared flu-
orescence imaging within the wavelength range of 650–
950  nm offers several advantages for tumor and in  vivo 
imaging owing to its low absorption and auto-fluores-
cence from organisms and tissues in the near-infrared 
spectral range, which can minimize background interfer-
ence, improve tissue depth penetration, image sensitivity 
and function noninvasively [13, 14]. Indium phosphide 
(core)-zinc sulfide (shell) InP@ZnS core–shell nanocom-
posites exhibit a very large stock shift, which leads to the 
appearance of near-infrared region fluorescent emission. 
With high quality, low toxicity and bright luminescence, 
InP@ZnS QDs have been used in diagnostic near-infra-
red imaging for the early detection of cancer [15, 16]. 
Herein, we report the physicochemical characteristics 
and bioapplications of novel hybrid nanocomposites of 
graphene oxide and InP@ZnS QDs that are bound to bio-
molecules (P-gp antibody) for multimodal targeting and 
treatment of drug-resistant cancer.
With the development of biotechnology, microRNAs 
(miRNAs) have been considered as important biomarkers 
since abnormal expression of specific miRNAs is associ-
ated with many diseases such as cancer, and the under-
standing of a variety of miRNA regulatory pathways in 
liver cancer has been gradually growing [17]. In multiple 
expression research of miRNAs profile, the expression of 
miR-122 in many hepatoma cells lines was found to be 
down-regulated. As a hepatic-abundant miRNA, miR-
122 is involved in the regulation of cancer cell migration 
and chemoresistance in liver. And with increased miR-
122 expression, the intrahepatic metastasis of liver cancer 
is significantly reduced or absent. In hepatoma tissues, 
the cyclin G1/tumor suppressor gene p53, apoptosis 
inhibitor gene Bcl-W and other related genes are targets 
of miR-122 [18, 19]. Based on its biological mechanisms 
and relatively low toxicity, miR-122 was chosen to control 
drug-resistant hepatocellular carcinoma cell growth and 
apoptosis in our study.
In our previous work, we exploited the possibility 
of combining the properties of gold nanoclusters and 
reduced graphene oxide (RGO) to design nanocompos-
ites suitable for drug delivery to and imaging of cancer 
cells [20]. In the following study, we intended to develop 
a combination of monoclonal P-glycoprotein (P-gp) anti-
bodies and miR-122 loaded on graphene oxide InP@ZnS 
QDs (GPMQNs), which should promote drug-resistant 
tumor cell apoptosis and exhibit targeted controlled-
release properties. Due to the function of the P-gp anti-
body, the GPMQNs could provide targeted drug delivery. 
On the other hand, combining with glutathione (GSH) 
could displace miR-122, which helped to control drug 
release.
GPMQNs were used to induce the apoptosis of drug-
resistant human HepG2/ADM hepatoma cells. Mean-
while, apoptosis-related proteins and the apoptosis 
signaling pathway were investigated. And the ability 
of the GPMQNs to provide near-infrared imaging of 
HepG2/ADM tumors was also explored. In conclusion, 
the present study could provide innovative therapeutic 
approaches for cancer treatments with following advan-
tages. (1) Inhibition of tumor growth and induction of 
tumor cell apoptosis by GPMQNs were demonstrated 
in vitro and in vivo, with the characteristics of high selec-
tivity and specificity toward target cancer cells with low 
cytotoxicity and controlled release. (2) miR-122 was 
selected instead of chemical drugs due to its higher safety 
and avoidance of MDR for chemotherapy. (3) Photother-
mal therapy to kill cancer cells could be applied by excit-




Sodium chloride (NaCl), sulfuric acid (H2SO4), potas-
sium permanganate (KMnO4), hydrochloric acid 
(HCl), sodium hydroxide (NaOH), chloroacetic acid, 
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), 
tris(trimethylsilyl)phosphine (P(TMS)3, 1-octylamine, 
1-octadecene (ODE), indium acetate (In(AC)3), myristic 
acid (MA), and amine were purchased from Shanghai 
Chemical Reagent Co. Ltd (China). RPMI-1640 medium 
and fetal calf serum (FCS) were purchased from Thermo 
Fisher Scientific (USA). Penicillin, streptomycin, adria-
mycin, GSH, acridine orange/ethidium bromide (AO/
EB), 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT), dimethyl sulfoxide (DMSO), 
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hematoxylin-eosin (HE) were purchased from Sigma-
Aldrich (USA). MiR-122 was synthesized by Shanghai 
Sangon Biologic Engineering Technology and Service Co. 
Ltd. (China).
Graphene oxide was self-made. The synthesis process 
of graphene oxide loaded with P-gp antibody (Sigma-
Aldrich, USA) was described as following. 1 g graphite and 
50 g NaCl were milled for 10 min and dissolved in water. 
The ground material was stirred for 8 h with 98% H2SO4 
(23 mL). Next, 3 g KMnO4 was gradually added to the mix-
ture, and the reaction temperature was maintained below 
20  °C. Then, the solution was mixed at 38  °C for 30 min 
and stirred at 70  °C for 45  min, and H2O (46  mL) was 
added, after which the mixture was maintained at 98 °C for 
30 min prior to the gradual addition of 30% H2O2 (10 mL). 
After filtration and recovery, 5% HCl was used to dis-
solve the filter material, which was then further dissolved 
in double-distilled H2O (ddH2O). The graphene oxide 
(1 mg, 1.5 mg mL−1) of different sizes was separated using 
gradient centrifugation at the following centrifugal con-
ditions: 10,000 rpm 2 h, 20,000 rpm 2 h, 30,000 rpm 2 h, 
40,000 rpm 2 h, and 50,000 rpm 2 h. Then, the centrifuged 
nanocompounds were vacuum dried at room tempera-
ture. Transmission electron microscope (TEM, JEM2100, 
JEOL, JPN) was used to observe the samples morphology. 
Graphene oxide (5 mL, 2 mg mL−1) of 300 nm diameter 
was treated with ultrasound for 1 h. 1.2 g NaOH and 1 g 
chloroacetic acid (Cl–CH2–COOH) were added into the 
solution, which was then treated with ultrasound for 2 h 
to form carboxylic acids on the grapheme oxide. To cross-
link P-gp antibodies onto the graphene oxide, the P-gp 
antibody was quantitatively added into the graphene oxide 
solution, and an EDC catalytic reaction was performed 
at room temperature, followed by vacuum drying and 
enhanced chemiluminescence (ECL, GE Healthcare Life 
Sciences, USA) detection.
InP@ZnS QD synthesis process was described as 
following. The injection solution was prepared using 
0.2  mM P(TMS)3 (Alf. 95%) and 2.4  mM 1-octylamine 
(Alf. 99%) dissolved in ODE (1.5 mL in total) in a glove 
box. In a typical synthesis, 0.4 mM In(AC)3 (Alf. 99.99%), 
1.54 mM MA (Alf. 98%) and 4 g ODE were loaded into 
a three-neck flask in the total volume of 1  L. The mix-
ture was heated to 188 °C under argon flow, and then the 
P(TMS)3/amine solution prepared in the glove box was 
injected into the hot reaction mixture. The cold injec-
tion solution brought the reaction temperature down 
to 178  °C for InP nanocrystals growth. To monitor the 
nanocrystals growth, aliquots were taken at different 
reaction times for absorption measurements [21].
Preparation and characterization of the GPMQNs sys-
tem: 1  mg P-gp antibody-modified graphene oxide was 
added to 1 mL chitosan solution (0.5 mg mL−1, 1% HAc, 
pH 5) and was treated with ultrasound for 1 h. The final 
product and 0.5 mL (0.001 mg mL−1) miR-122-InP@ZnS 
QDs were mixed and then stirred overnight. The end 
product of the GPMQNs reaction was vacuum dried. 
TEM was used to characterize the morphology of the 
GPMQNs. The same amount of miR-122 and GPMQNs 
were analyzed using agarose gel electrophoresis in the 
miR-122 GSH-release experiments with added GSH. 
The fluorescence emission spectrum of GPMQN was 
recorded using a fibre optic charge coupled device (CCD) 
spectrometer (USB4000, Ocean Optics Inc., USA). For 
the absolute quantum yield measurement, a spec-trome-
ter incorporating an integrating sphere was used (C9920-
02, Hamamatsu, JPN). Mean sizes analyses for GPMQN 
were evaluated by dynamic light-scattering using Zeta-
sizer (size range: 1 nm¨1 mm, Malvern Instruments Ltd., 
UK), a photo-correlation spectroscopy apparatus.
Nucleic acid release assay: the same amounts of miR-
122 of the GPMQN were loaded into the wells of an aga-
rose gel to perform electrophoresis to detect GSH for 
miR-122 in the sustained-release experiment. For the 
well without GSH added, no nucleic acid showed bands.
GPMQNs uptake analysis with near‑infrared imaging 
in vitro
HepG2 cells were maintained in RPMI-1640 medium 
containing 10% FCS, 100  U  mL−1 of penicillin, and 
100 μg mL−1 of streptomycin at 37  °C with 5% CO2. To 
develop the drug resistant cell line (HepG2/ADM), adria-
mycin was added to HepG2 cells in stepwise increasing 
concentrations, from 0.05 to 2  µg  mL−1 over 8  months. 
HepG2/ADM cells were cultured in 6-well plates, and 
then were treated with GPMQNs for 1  h. After the 
washing of the cells, confocal fluorescence microscopy 
(excitation wavelength at 600  nm) was used to observe 
the intracellular near-infrared fluorescence (CarlZeiss 
LSM710, Carl Zeiss, German), and small animal imaging 
experiments were used to observe the intracellular near-
infrared fluorescence.
HepG2/ADM cells were seeded in a 96-well plate 
(2 × 103 cells/well). After an overnight culture, the cells 
were treated with miR-122 in Lipofectamine-2000, 
GPMQNs without miR-122, or GPMQNs. The effect of 
GPMQNs on cancer cell membrane permeability was 
determined using a lactate dehydrogenase (LDH, Thermo 
Fisher Scientific, USA) cytotoxicity assay.
Apoptosis induced by GPMQNs treatment in vitro
HepG2/ADM cells were cultured in 6-well plates and 
then treated with 10 mg L−1 GPMQNs for 24 h. After the 
washing, the morphology of the HepG2/ADM cells was 
observed using confocal fluorescence microscopy experi-
ments (excitation wavelength at 600 nm).
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HepG2/ADM cells treated with 10  mg  L−1 GPMQNs 
were stained with an AO/EB dye mixture and viewed 
under a fluorescence microscope.
HepG2/ADM cells were plated in 96-well plates 
(2 × 103 cells/well). After overnight incubation, the cells 
were treated with various concentrations of GPMQNs. 
After 36 h, a 20 μL MTT solution (5 mg/mL) aliquot was 
added into each well. After 4 h of incubation, the super-
natant was removed, and 100  μL DMSO was added to 
each well. The samples were then shaken for 15  min 
before the optical density was measured at a wavelength 
of 540 nm. All experiments were performed in triplicate. 
The relative inhibition of cell growth was expressed as 
follows: 
GPMQNs used for HepG2/ADM in  vitro laser hyper-
thermia (SLIM-532, Oxxius, France): the laser irradia-
tion experiment involved choosing different wavelengths 
of semiconductor lasers. HepG2/ADM cells were added 
to the GPMQNs solution, exposed to a power density of 
20 W/cm−2 of the semiconductor laser light source and 
irradiated for 1 min prior to trypan blue staining.
Detection of HepG2/ADM cell DNA fragmenta-
tion and apoptosis by flow cytometry (BD Accuri C6, 
BD, USA): HepG2/ADM cells were treated with miR-
122-Lipofectamine 2000, GPMQNs without miR-122, or 
GPMQNs treatment. The apoptosis rate was evaluated 
using flow cytometry. Apoptotic DNA in the HepG2/
ADM cells was explored using an Apoptotic DNA Lad-
der Isolation Kit (Biovision, USA) and then separated by 
agarose gel electrophoresis.
The mechanism of HepG2/ADM cell apoptosis was 
explored using Western blotting. HepG2/ADM cells were 
treated with miR-122-Lipofectamine 2000, GPMQNs 
without miR-122, or GPMQNs for 72  h, and the total 
proteins were extracted using radioimmunoprecipita-
tion assay (RIPA) buffer (Thermo Fisher Scientific, USA). 
The protein concentration was determined using a BCA 
kit (Bio-Rad, USA). Proteins (15  μg) were separated by 
SDS-PAGE and transferred to nitrocellulose membranes 
(GE Healthcare Life Sciences, USA). The membranes 
were blocked in 5% non-fat dry milk followed by incuba-
tion with primary antibodies. Then, the membranes were 
incubated with goat anti-rabbit IgG horseradish per-
oxidase (HRP)-conjugated secondary antibodies (1:2000, 
7074, Cell Signaling Technology (CST), Inc., USA) and 
developed using ECL (GE Healthcare Life Sciences, 
USA). To study the related signal transduction path-
ways, antibodies were used to detect the activated forms 
of caspase 8 (death receptor pathway), caspase 9 (mito-
chondrial pathway), caspases 7, 3, 1, proteolytic cleav-
age of poly-(ADP-ribose) polymerase (PARP), Bcl-2, and 
Cell viability % = ([OD]test/[OD]control) × 100%.
Bcl-w, with glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) expression level as a control. The primary anti-
bodies used were as follows: anti-caspase 8 (1:1000; 9496, 
CST, USA), anti-caspase 9 (1:1000; 9502, CST, USA), 
anti-caspases 7 (1:1000; 8438, CST, USA), anti-caspases 3 
(1:1000; 9654, CST, USA), anti-caspases 1 (1:1000; 4199, 
CST, USA), anti-PARP (1:1000; 5625, CST, USA), anti-
Bcl-2 (1:1000; 2872, CST, USA), anti-Bcl-w (1:1000; 2724, 
CST, USA), anti-GAPDH (1:1000; 2118, CST, USA) rab-
bit monoclonal antibody.
GPMQNs treatment to HepG2/ADM tumor‑bearing mice 
for near‑infrared imaging in vivo
Mice used in this study were housed in the mouse facility 
of Model Animal Research Center, Nanjing Medical Uni-
versity, in accordance with Institutional Animal Care and 
Use Committee (IACUC) approved protocol.
Establishment of the drug-resistant HepG2/ADM nude 
mice tumor model: HepG2/ADM cells in the logarithmic 
growth phase were injected into nude mice, and the ani-
mals were divided into four groups, each group with 5 
mice: (1) normal saline, (2) GPMQNs without miR-122, 
(3) miR-122-Lipofectamine 2000, and (4) GPMQNs. The 
tumor cells were inoculated a week later; when the tumor 
grew to approximately 50  mm3 in size, the four groups 
of nude mice received tail vein injections of the various 
treatments at 0, 2, 4, 6, 8, 10, 12, 14, 16, and 18 days. On 
the twentieth day, the tumor was removed and formalin 
fixed; the size of the tumor was calculated using the for-
mula V = pi/6 × [(A + B)/2]3, where A represents the 
maximum tumor diameter and B represents the mini-
mum diameter of the tumor.
The animals were anesthetized intraperitoneally and 
were placed on the table in a side position so that the 
detector was positioned on the tumor region of the ani-
mal. Small animal in vivo imaging was performed using 
Lumina XR instruments with excitation wavelength at 
600 nm (Caliper Life Science, Inc., USA).
Establishment of tumor cell model in vivo for HepG2/ADM 
cell apoptosis analysis
In vivo cell apoptosis analysis: histology of tumor tissue 
from experimental nude mice. Tumor tissue sections 
were embedded in paraffin wax, and HE staining was 
performed for detection of cell apoptosis. Five mice from 
each group were sacrificed at 5  weeks to obtain mice 
organs (bone, skin, muscle, intestine, liver and tumor). 
Tissues were digested to measure In and Zn levels. All 
organs were washed with distilled deionized water and 
dried on paper towels. The samples were dried to con-
stant weight at 105  °C. The organs were then ground in 
an agate mortar and digested in aqua regia. After appro-
priate dilution with ddH2O, the metal concentrations 
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in the samples were determined by atomic absorption 
spectrophotometry.
Statistical analysis
Results were presented as mean  ±  standard deviation 
(SD). A t test was performed in each group for each time 




InP QDs loaded with miR-122 were synthesized and 
identified by TEM imaging. The average size of the InP 
QDs was approximately 3  nm (Fig.  1Aa, Ab). However, 
we found that the InP QDs and miR-122 complexes were 
approximately 20 nm (Fig. 1Ba). Thus, we speculated that 
an abundant amount of miR-122 could be loaded onto 
the InP QDs. As shown in Fig. 1Bb, the GPMQNs nano-
composites (300 nm) were synthesized and characterized. 
The GPMQNs were also characterized by dynamic light 
scattering, which measured the hydrodynamic diam-
eter of the nanocomposites in their dispersion state. The 
mean size of GPMQNs measured in the culture medium 
was about 300 nm (Fig. 1C). The TEM image indicated a 
homogeneous distribution of InP QDs on the P-gp anti-
body-graphene oxide surface with chitosan functionali-
zation. To quantify fluorescence yield of QDs reduced by 
graphene, we have performed fluorescence yield assess-
ment. We find quantum yields of InP in GPMQNs was 
not reduced due to the InP fluorescence was near-infra-
red fluorescence (Fig. 1D). As expected, a small amount 
of miR-122 of the same size as pure miR-122 (Fig. 1F, lane 
1) was released when the concentration of GSH reached 
2 mM (Fig. 1F, lane 4). The mobility of miR-122 recovered 
completely when the final GSH concentration reached 
10  mM (Fig.  1F, lane 5). We demonstrated that the InP 
QDs completely prevented miR-122 from moving to the 
positive electrode (Fig. 1F, lane 2). The positively charged 
InP QDs may have counteracted the negative charges of 
miR-122. However, negatively charged GSH containing 
a thiol has stronger affinity to InP QDs and the addition 
of GSH was demonstrated to potentially counteract the 
positive charge of the InP QDs to some extent by ligand 
exchange, resulting in the release of miR-122 from the 
InP QDs. As shown in Fig. 1, the release of miR-122 from 
the InP QDs was quantified using a nucleic acid release 
assay, and the results were consistent with the electro-
phoresis experiment (Fig.  1E). The typical near-infrared 
fluorescence spectrum of the GPMQNs was approxi-
mately 650 nm, as shown in Fig. 1G. Moreover, we also 
illustrated that the P-gp antibody could be effectively 
absorbed by graphene oxide (Fig.  1H). The results sug-
gested that P-gp antibody-graphene oxide and GSH 
might play a critical role in combining miR-122 with 
GPMQNs to enhance the targeting of miR-122 to cancer 
cells. The relevant miR-122 loading efficiency was fur-
ther determined by OD analysis, which indicated that the 
miR-122 loading onto the GPMQNs was approximately 
10%.
Near‑infrared cellular GPMQNs image analysis 
and intracellular miR‑122 accumulation assay
Based on the above research, the near-infrared bio-
imaging of GPMQNs in HepG2/ADM cell lines was 
performed using inverted fluorescence microscopy. The 
near-infrared intracellular fluorescence of HepG2/ADM 
cells treated with GPMQNs was detected (Fig.  2A, B). 
The three dimensional (3D) reconstruction of HepG2/
ADM cells treated with GPMQNs demonstrated higher 
intracellular near-infrared GPMQNs distribution 
(Fig. 2C).
The intracellular fluorescence in HepG2/ADM cells 
increased dramatically upon treatment with GPMQNs 
containing red fluorescence-modified miR-122 (Fig. 2Dc), 
compared with the transfected miR-122 group (Fig. 2Db). 
The results illustrated that the intracellular miR-122 con-
tent was increased after treatment with GPMQNs.
GPMQNs also exhibited an increased impact on cell 
permeability, as compared with the miR-122 transfection 
and GPMQNs without miR-122 groups (Fig. 2E).
Apoptosis analysis in GPMQN‑treated cancer cells
The evaluation of normal or apoptotic cells depends 
on their morphological characteristics. Apoptotic cell 
membranes (shrinkage, irregular membrane, Fig.  3A) 
were easily distinguished from normal cell membranes 
(smooth membrane, Fig.  3B). To further determine the 
apoptotic effect of GPMQNs in HepG2/ADM cells, an 
AO/EB staining assay was used. Apoptotic nuclei were 
identified by their characteristic features such as chro-
mosomal condensation, distinctive margination and 
fragmentation using fluorescence microscopy. The apop-
totic nuclei of HepG2/ADM cells (Fig. 3D, late apoptotic 
nuclei) treated with GPMQNs for 48  h could be clearly 
identified by their distinctively red margins and frag-
mented appearance, compared with the green early apop-
totic appearance of cells treated for 24  h (Fig.  3C, early 
apoptotic nuclei). In the untreated control cells, the cell 
nuclei were normal, as shown in Fig. 3Ca, Db. Moreover, 
with increasing GPMQNs concentrations, the growth of 
the HepG2/ADM cells was strongly suppressed (Fig. 3E, 
Additional file 1). And the MTT result showed that IC50 
value of GPMQNs to HepG2/ADM cells was about the 
concentration of 1.2 mg mL−1.
To further explore the multifunctional anticancer 
effect of GPMQNs on HepG2/ADM cells, they were 
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Fig. 1 Synthesis and characterization of miR-122-InP QDs-loaded graphene oxide composites. Aa Low magnification image of InP QDs (Scale bar 
20 nm). Ab HRTEM image of InP QDs (Scale bar 3 nm). Ba TEM image of miR-122-InP QDs-loaded graphene oxide composites (Scale bar 50 nm). 
Bb TEM image of GPMQN (Scale bar 50 nm). C Size distribution of GPMQN in the culture medium characterized by dynamic light scattering. D 
Calculating quantum yields of GPMQNs (a) and compare with bare QDs (b); (c) Histograms of quantum yields of GPMQNs (a) and compare with 
bare QDs (b). E Verified function of miR-122 by GSH through AO fluorescence assay; 1 AO + miR-122, 2 AO + GPMQN, 3 AO + GPMQNs + 0.2 mM 
GSH, 4 AO + GPMQNs + 1 mM GSH, 5 AO + GPMQN + 5 mM GSH, 6 AO + GPMQN + 10 mM GSH. F Confirmed function of miR-122 release by 
GSH through agarose gel electrophoresis assay; 1 AO + miR-122, 2 AO + GPMQN, 3 AO + GPMQN + 0.2 mM GSH, 4 AO + GPMQN + 1 mM GSH, 5 
AO + GPMQN + 5 mM GSH, 6 AO + GPMQN + 10 mM GSH. G Emission spectrum of GPMQN, excitation wavelength at 650 nm. H Quantification of 
P-gp antibody remaining in solution; 1 0 h, 2 1 h, 3 4 h, 4 8 h, 5 12 h exposure to graphene oxide (*P < 0.05 compared to the control group)
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probed with a semiconductor laser to perform a hyper-
thermia experiment. As shown in Fig.  3F, HepG2/ADM 
cells treated with GPMQNs were severely damaged at 
Fig. 2 A Cellular near-infrared fluorescence and GPMQNs uptake. 
Inverted fluorescence microscopy of HepG2/ADM cells with 
10 mg L−1 GPMQNs, B Control (Scale bar 50 μm). B 3D reconstruction 
of HepG2/ADM cells treated with 10 mg L−1. GPMQNs of near-
infrared fluorescence for intracellular distribution (Scale bar 50 μm). 
D Whole body optical imaging examination of HepG2/ADM cells 
incubated with identical 10 mg L−1 GPMQNs solutions after 24 h 
incubation; a Control, b 1 mg L−1 red fluorescent modified miR-122, c 
10 mg L−1 GPMQNs containing the red fluorescent modified miR-122. 
E Quantitative assay of GPMQNs on cell membrane permeability 
based on the LDH release assay; 1 untreated control, 2 resistant 
HepG2/ADM cells transfected with miR-122 (1 mg L−1, same concen-
tration as loaded on GPMQN), 3 resistant HepG2/ADM cells incuba-
tion with 10 mg L−1 GPMQNs without miR-122, 4 resistant HepG2/
ADM cells incubation with 10 mg L−1 GPMQNs (*P < 0.05 compared 
to the control group)
Fig. 3 A Morphological image of HepG2/ADM cells incubated 
with 10 mg mL−1 GPMQNs (→, amplification image) for 24 h 
(Scale bar = 50 μm); B Control. Detection of apoptotic cells by AO/
EB Staining, (Panels C, D) apoptotic nuclei from HepG2/ADM cells 
identified by their distinctively marginated and fragmented appear-
ance. Control cell nuclei cells are observed (Panels Ca, Db) (Scale 
bar 50 μm). E Increased growth rate checked by GPMQNs treat-
ments in HepG2/ADM cells. HepG2/ADM cells were treated with 
1 0 mg mL−1 GPMQNs (as control), 2 1 × 10−4 mg mL−1 GPMQNs, 
3 1 × 10−3 mg mL−1 GPMQNs, 4 1 × 10−2 mg mL−1 GPMQNs, 5 
1 × 10−1 mg mL−1 GPMQNs, 6 1 mg mL−1 GPMQNs, 7 10 mg mL−1 
GPMQNs. Photothermal therapy assay of HepG2/ADM cells treated 
with GPMQNs. F Images of photothermal therapy for cells with 
10 mg L−1 GPMQNs with laser power threshold of 20 W cm−2 for 
1 min; G Without treatment as control. (Scale bar 20 μm), (*P < 0.05 
compared to the control group)
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a laser power threshold of 20 W cm−2 for 1 min. How-
ever, no photothermal destruction was observed for 
HepG2/ADM cell treated with miR-122 at the condition 
described above (Fig. 3G).
Molecular mechanisms underlying GPMQNs 
treatment‑induced apoptosis
Using Annexin-V-FITC labeling, the apoptosis induction 
in treated HepG2/ADM cells was confirmed (Fig.  4A). 
Significantly, in comparison to the control treatment, 
the growth inhibition rate was increased when HepG2/
ADM cells were treated with gradient concentrations of 
GPMQNs. Meanwhile, the percentage of apoptotic cells 
was 68, 66.1, 65.4, 60.3, 55.6, and 8.8% for cells incubated 
with 10 mg L−1 GPMQNs, 8 mg L−1 GPMQNs, 4 mg L−1 
GPMQNs, 2 mg L−1 GPMQNs, 1 mg L−1 GPMQNs, and 
control treatment, respectively.
Furthermore, cell apoptosis induced by GPMQNs treat-
ment was confirmed using a DNA fragmentation assay. 
When HepG2/ADM cells were treated with GPMQNs, 
the intensity of the fragmented chromosomal DNA bands 
(Fig.  4B, lane 4) was much higher than that observed in 
cells treated with miR-122 (Fig.  4B, lane 3) or GPMQNs 
without miR-122 (Fig. 4B, lane 2). To explore the molecu-
lar mechanisms underlying GPMQNs-induced apoptosis, 
the expression of apoptosis-related proteins in the cells 
was examined. As shown in Fig. 4C, the protein levels of 
Bcl-w, which is a target gene of miR-122, was reduced 
in HepG2/ADM cells after treatment with GPMQNs. 
Moreover, the cleaved caspase 8 and 9 signals were much 
stronger in cells treated with GPMQNs (Fig.  4C, lane 4) 
than in cells treated with GPMQNs without miR-122 or 
with miR-122 alone (Fig. 4C, lane 2 and 3). The strongest 
activation of caspases 8 and 9 occurred after GPMQNs 
treatment (Fig. 4C, lane 4). Similar results were obtained 
for cleaved caspases 7, 3, and 1 and cleaved PARP, which is 
a downstream element of the caspase 7, 3, and 1 pathway. 
The Bcl-2 signal in the HepG2/ADM cells was weaker after 
GPMQNs treatment than after treatment with GPMQNs 
without miR-122 or miR-122 alone (Fig. 4C, lanes 4, 3, and 
2, respectively). This result suggested that GPMQNs treat-
ment induced the inhibition of antiapoptotic protein acti-
vation and caused apoptosis by the activation of caspases 9 
and 8 and the Bcl-2 pathway in HepG2/ADM cells.
Target Tumor Imaging in vivo
Finally, the fluorescence of GPMQNs labeled by differ-
ent fluorescent dyes was detected in  vitro and in  vivo. 
As shown in Fig.  5 A and B, 6-week-old nude mice 
were subcutaneously implanted with 106 HepG2/ADM 
Fig. 4 Apoptotic assay of HepG2/ADM cells induced by GPMQNs. 
A Flow cytometric measurement of cellular apoptosis of resistant 
HepG2/ADM cells treated with various reagents; a untreated cells, b 
treatment of cells with 1 mg L−1 GPMQNs, c treatment of cells with 
2 mg L−1 GPMQNs, d transfected cells with 4 mg L−1 GPMQNs, e 
transfected cells with 8 mg L−1 GPMQNs, f treatment of cells with 
10 mg L−1 GPMQNs, g histograms of apoptotic rate of HepG2/ADM 
after various treatments as shown in (a, b, c, d, e, f). B DNA fragmen-
tation in resistant HepG2/ADM cells after different treatments; 1 
untreated cells, 2 treatment of cells with 10 mg L−1 GPMQNs without 
loading miR-122, 3 transfected cells with miR-122 (1 mg L−1, same 
concentration as loaded on GPMQNs), 4 treatment of cells with 
10 mg L−1 GPMQNs. C Western blot analysis after various treatments; 
1 untreated cells, 2 treatment of cells with 10 mg L−1 GPMQNs 
without loading miR-122, 3 transfected cells with miR-122 (1 mg L−1, 
same concentration as loaded on GPMQNs), 4 treatment of cells with 
10 mg L−1 GPMQNs, (*P < 0.05 compared to the control group)
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tumor cells, which were treated with green fluorescent 
dye-labeled GPMQNs. Tumors of mice treated with the 
labeled GPMQNs could produce fluorescence spontane-
ously. The results illustrated that the intracellular miR-
122 content was increased after treatment with GPMQNs 
in vivo.
The near-infrared fluorescence intensity of tumors after 
an intravenous injection of 10 mg kg−1 of GPMQNs was 
reduced as the treatment time increased (Fig.  5C). To 
further test the hypothesis that P-gp antibodies can be 
used to target drug-resistant tumors, nude mice bearing 
HepG2/ADM tumors were treated with an intravenous 
injection of GPMQNs. Near-infrared imaging demon-
strated that nude mouse tumors treated with GPMQNs 
exhibited significant tumor uptake of near-infrared InP 
QDs in the right lower abdomen of mice from coronal, 
sagittal, transaxial images (Fig.  5D). 3D reconstruction 
of nude mice treated with GPMQNs demonstrated that 
the near-infrared InP QDs fluorescence imaging has 
been shown to successfully track as fluorescently marked 
probes. As demonstrated in Fig.  5E, the tumor location 
could be determined in the HepG2/ADM tumor model 
clearly and accurately over time by using the 3D repre-
sentation of GPMQNs.
Suppression of tumor growth by GPMQNs in nude mice
To investigate the effects of GPMQNs on HepG2/ADM 
tumors in vivo, nude mice were inoculated with HepG2/
ADM cells, and the subsequent tumor growth was 
recorded after various treatments. HepG2/ADM tumor-
bearing mice without any treatment exhibited the largest 
tumor volume (3690 mm3, Fig. 6Aa, group 1). The tumor 
size of the mice treated with GPMQNs (Fig. 6Ad, group 
4) was significantly reduced, compared to that of the con-
trol group (Fig. 6Aa, group 1) and the groups treated with 
GPMQNs without miR-122 (Fig. 6Ab, group 2) or miR-
122 alone (Fig. 6Ac, group 3).
The synergistic effect of GPMQNs on apoptosis induc-
tion in the HepG2/ADM xenograft tumors excised from 
the nude mice was evaluated (Fig.  6B). As control, the 
apoptosis rate in the group 1 (untreated HepG2/ADM 
xenograft tumors, Fig.  6Ba) was approximately 8%. The 
apoptosis rate in group 2 (treated with GPMQNs without 
miR-122, Fig. 6Bb) did not increase significantly, was only 
23%. However, in group 3 (treated with miR-122 alone, 
Fig. 6Bc) and group 4 (treated with GPMQNs, Fig. 6Bd), 
the numbers of apoptotic cells were 34 and 68%, respec-
tively, and were considerably higher in comparison to the 
control.
To investigate the distribution of GPMQNs in  vivo, 
the tissue uptake of InP QDs was examined. Figure  6D 
shows the distribution of In levels in various organs. 
In the mice of group 3 (treated with miR-122 only), the 
organ distribution of In was the same as that of the con-
trol group (Fig. 6D, group 1). However, when GPMQNs 
were injected into the nude mice of groups 3 and 4, the 
amount of indium element in all tested organs was higher 
than the amount in the control group, especially in the 
tumor, intestines and liver.
Fig. 5 Image of tumor cells in vivo. Fluorescence image of tumor 
after intravenous injection of 10 mg kg−1 GPMQNs (miR-122 with 
green fluorescent) solution for 2 h; A fluorescence intensity scan 
of xenograft tumor, B green fluorescence near the tumor. C Near-
infrared fluorescence image of tumor after intravenous injection of 
10 mg kg−1 GPMQNs solution; a treatment for 2 h, b treatment for 
4 h, c treatment for 8 h, d treatment for 16 h. D 3D reconstruction 
of HepG2/ADM xenograft tumors in different directions; a coronal 
image, b sagittal image, c transaxial image. E 3D reconstruction of 
HepG2/ADM xenograft tumors image
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Discussion
As a novel delivery tool, InP QDs (positively charged) 
could be easily fixed non-coding RNAs miR-122 (nega-
tively charged). InP QDs and miR-122 are amphiphilic 
substances (both positive and negative electrical attrac-
tion) that form the core–shell structure of the miR-
122-containing nanocarriers. Bao et  al. [22] have 
developed chitosan functionalized graphene oxide as a 
nanocarrier for drug and gene delivery. InP QDs-miR-122 
formed a nanocomposite that was further adhered onto 
grapheme oxide. In reality, the size of the graphene oxide 
is a problem that affects its use as a drug carrier. If the 
graphene oxide sizes are too large, drug delivery in the 
blood stream would be affected. Whereas if graphene 
oxide sizes are too small, drug loading would be affected, 
and particle phagocytosis would readily occur [23]. Thus, 
in the present study, we concluded that the size of gra-
phene oxide should be approximately 300 nm (achieved 
through gradient centrifugation) to ensure its drug load-
ing and to avoid phagocytosis by phagocytic cells in vivo. 
As mentioned above, this size range could make use of 
nano-drug biodistribution through the enhanced perme-
ability and retention effect to target tumors.
GSH was able to control the miR-122 release from the 
GPMQNs by ligand displacement, so we could achieve 
sustained controlled release of miR-122 in cancer cells. The 
concentration of GSH in erythrocytes was 2 mM, whereas 
it was 10 mM in the HepG2/ADM cells. Due to the P-gp 
antibody, the GPMQNs could target to the HepG2/ADM 
cell membrane. In this study, cancer cells were targeted via 
antigen–antibody interactions. As described above, InP 
QDs loaded with miR-122 were formed as nanocompos-
ites, and the nanocomposite was adhered onto graphene 
oxide to induce the apoptosis of drug-resistant cancer cells 
(InP QDs incorporated onto the graphene oxide with chi-
tosan functionalization). As the predominant low-molecu-
lar-weight thiol in animal cells, GSH provided a potential 
environment for miR-122 entry into HepG2/ADM cells 
[24]. Besides its pleiotropic metabolic effects, miR-122 was 
selected instead of chemical drugs for another two reasons: 
to avoid the high toxicity of chemical drugs, and attempt to 
avoid multi-drug resistance to chemotherapy [25].
HepG2/ADM membrane permeability and intracellu-
lar miR-122 accumulation assays were performed. After 
GPMQNs treatment, an increase in the amount of intra-
cellular miR-122 was observed in the HepG2/ADM cells. 
It demonstrated that cell membrane permeability was 
significantly increased by GPMQNs treatment, which 
induced the uptake of miR-122 in HepG2/ADM cells. 
These results suggested that the InP QDs could be readily 
internalized by cells for drug delivery.
Fig. 6 GPMQN therapy assay of HepG2/ADM cells treated with 
GPMQNs. A Inhibition of tumor growth in HepG2/ADM nude mice 
with different treatments, a untreated used as control, b treated 
10 mg kg−1 GPMQNs without loading miR-122, c transfected with 
miR-122 (1 mg kg−1, same concentration as loaded on GPMQNs), 
d treated 10 mg kg−1 GPMQNs. B HE staining was performed on 
tissue sections of HepG2/ADM xenograft tumors treated as follows: 
a untreated used as control, b treated 10 mg kg−1 GPMQNs without 
loading miR-122, c transfected with miR-122 (1 mg kg−1, same con-
centration as loaded on GPMQNs), d treated 10 mg kg−1 GPMQNs. 
C The effect of different treatments on the tumor growth inhibition 
in HepG2/ADM nude mice. a untreated used as control, b treated 
10 mg kg−1 GPMQNs without loading miR-122, c transfected with 
miR-122 (1 mg kg−1, same concentration as loaded on GPMQNs), d 
treated 10 mg L−1 GPMQNs. D Distribution of indium levels in various 
tissues from different treatment groups. The HepG2/ADM nude mice 
were treated the same way as shown in (C). 1 Brain, 2 Muscle, 3 Skin, 4 
Liver, 5 Intestine, 6 Tumor. (*P < 0.05 compared to the control group)
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Photothermal activity can deposit a sufficient amount 
of energy into tissue under appropriate conditions to raise 
the temperature above a certain threshold so that cancer 
cell destruction would occur. Multifunctional GPMQNs 
have been proven to effectively enhance the photother-
mal killing of tumor cells by lasers in  vitro. As shown 
in the results, cancer cells treated with GPMQNs were 
destroyed at the laser power threshold of 20 W cm−2 for 
1 min, and the tumor growth was suppressed. This result 
was indeed consistent with earlier observations of laser 
treatments for photothermal therapy in vitro [26].
Next, the apoptotic effects of GPMQNs on HepG2/
ADM cells were further detected by MTT assay, nuclear 
staining, and a DNA fragment assay. The GPMQNs were 
demonstrated to exhibit an anti-proliferative effect in a 
dose-dependent manner in HepG2/ADM cells. Using 
AO/EB staining of apoptotic cells, apoptotic nuclei were 
identified by their distinctively marginated and frag-
mented appearance. The apoptotic nuclei of HepG2/
ADM cells at 48  h could be identified by their distinc-
tively marginated and fragmented appearance. In the 
control cells without treatment, the cell nuclei were nor-
mal. The apoptosis effects on the cell nuclei allow DNA 
extraction methods to generate apoptosis DNA ladders 
in apoptotic cells. To determine whether cell growth inhi-
bition was caused by the apoptotic response, we showed 
that the relevant GPMQNs induced a much higher 
cell apoptosis rate than the untreated control using an 
Annexin-V-FITC and PI apoptosis detection method. 
The apoptotic DNA ladders were examined by agarose 
gel electrophoresis. In HepG2/ADM cells treated with 
GPMQNs, the intensity of the apoptosis DNA ladders 
was much higher than that observed in untreated cells or 
cells treated with miR-122 alone. Our observations sup-
ported the hypothesis that the remarkable enhancement 
of apoptosis was induced by the synergistic effect of the 
GPMQNs. Anticancer research on the GPMQNs apop-
tosis signaling pathway was carried out as well. Accord-
ing to previous research reports, miR-122 could induce 
apoptosis through the Bcl-w pathway involving hepatoma 
therapy [27, 28]. However, the underlying molecular 
mechanisms of the induction of cancer cell apoptosis by 
graphene-InP QDs material and miR-122 remain unclear. 
This study highlighted the mechanism of apoptosis 
induction in drug-resistant HepG2/ADM cells treated by 
GPMQNs. We found that GPMQNs treatment activated 
the Bcl-w and caspase 8 and 9 pathways to induce apop-
tosis in HepG2/ADM cells. The cleaved caspase 8 and 9 
activated caspases 3, 7, and 1, which correlated with the 
increased cleaved PARP expression after GPMQNs treat-
ment. Apoptotic DNA ladders were induced during cell 
apoptosis by the expression of cleaved PARP.
Over the past two decades, cadmium chalcogenide 
QDs such as cadmium sulfide (CdS), cadmium selenide 
(CdSe), and cadmium telluride (CdTe) QDs have been 
extensively studied [29]. In particular, CdSe/ZnS (core/
shell) QDs have been well-studied in terms of synthe-
sis and its biological applications [30]. Because of the 
potential toxicity concerns for heavy metal ions such as 
Cd2+, other alternative QDs that do not contain heavy 
metal elements have been investigated, including InP/
ZnS (core/shell) QDs. Visible fluorescence penetration 
capability is very poor, and imaging with the above-men-
tioned QDs cannot be achieved in  vivo. For bioimaging 
applications that demand deep tissue penetration, near-
infrared fluorescence is more advantageous for QD emis-
sion because it provides greater tissue penetration due to 
reduced photon scattering and auto-fluorescence. Many 
near-infrared emitting QDs, including lead selenide 
(PbSe), CdTe/CdSe (core/shell), and lead sulfide (PbS), 
have been developed [31, 32]. These QDs also encounter 
the problem on high toxicity of heavy metal, however, the 
toxicity of InP QDs is relatively low. With tumor bioimag-
ing by fluorescent, the GPMQNs were found to enhance 
the imaging of HepG2/ADM tumor features in vivo. Such 
result was expected to improve the consistency of target 
volume measurements for treatment. The image results 
offer an advantage for applications that demand deep tis-
sue penetration target activity.
Meanwhile, the potential tumor inhibition effect of 
the GPMQNs, which affected cellular metabolism and 
increased the apoptosis of tumor cells, was explored 
in vivo. The anti-cancer effect of the GPMQNs was evalu-
ated by investigating the extent of apoptosis induction 
by HE staining in  vivo. In agreement with the in  vitro 
signal expression results, the HepG2/ADM tumors 
exhibited considerable induction of apoptosis-related 
proteins in mice treated with GPMQNs. Compared to 
the other groups, the indium concentration in the nude 
mice injected with GPMQNs was significantly higher 
in tumor tissues, and this phenomenon illustrated their 
targeting property. The following distribution tissues of 
indium were intestines and liver, and it was proposed that 
GPMQNs may be subsequently excreted via intestines or 
liver, which warranted further investigation.
Conclusions
In conclusion, our experimental results indicated 
that the delivery of miR-122 by the multifunctional 
GPMQNs would provide a novel and effective system 
to induce apoptosis and inhibit the growth of hepatic 
tumor cells. And herein, GPMQNs were demonstrated 
to possess the following advantages: (1) low toxicity, (2) 
selective targeting, (3) intracellular drug accumulation 
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enhancement, (4) apoptosis promotion of drug-resistant 
liver cancer cell, (5) the near-infrared imaging. There-
fore, GPMQNs may be a promising nano-strategy for 
treating drug-resistant hepatoma cells, which suggested 
that it warrants further evaluation as cancer therapeutics 
in clinical.
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